SCHEMBL60038

SCHEMBL60038

c1ccc(Cc2cnon2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CALM1 P0DP23 1/20 0.44
TAAR1 Q96RJ0 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
LMNA P02545 1/20 0.37
HTR2B P41595 1/20 0.37
JAK2 O60674 2/20 0.36
ROCK2 O75116 2/20 0.36
PRKACA P17612 2/20 0.36
CDK2 P24941 2/20 0.36
KDR P35968 2/20 0.36
GSK3B P49841 2/20 0.36
AURKB Q96GD4 2/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
CDK1 P06493 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27072915 0.70 CALM1 (0.55) ALDH1A1RAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL88635 0.68 ALDH1A1 (0.47) ALDH1A1RAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL5310901 0.66 IDO1 (0.39) TAAR1
SCHEMBL11330543 0.66 KCNH2 (0.62) ALDH1A1RAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL1325617 0.66 CALM1 (0.55) ALDH1A1SMN1; SMN2TDP1CALM1TAAR1
Diphenylmethane SCHEMBL14763944 0.65 CALM1 (1.00) ALDH1A1CALM1LMNAKDM4ECYP3A4
Diphenylmethane SCHEMBL1303 0.65 CALM1 (1.00) ALDH1A1CALM1LMNAKDM4ECYP3A4
Diphenylmethane SCHEMBL4361124 0.65 CALM1 (1.00) ALDH1A1CALM1LMNAKDM4ECYP3A4
Diphenylmethane SCHEMBL3792579 0.65 CALM1 (1.00) ALDH1A1CALM1LMNAKDM4ECYP3A4
Diphenylmethane SCHEMBL28172316 0.65 CALM1 (1.00) ALDH1A1CALM1LMNAKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1068 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025026422-A1 ARYL OR HETEROARYL SUBSTITUTED GLUTARIMIDE DERIVATIVE AND USE THEREOF 标新生物医药科技(上海)有限公司 2025-02-06 WO claimed
WO-2025016351-A1 COMPOUND BASED ON THIO-GLUTARIMIDO ISOINDOLINONE SKELETON AND USE THEREOF 标新生物医药科技(上海)有限公司 2025-01-23 WO claimed
WO-2025016350-A1 THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF 标新生物医药科技(上海)有限公司 2025-01-23 WO claimed
WO-2024245443-A1 COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-12-05 WO claimed
WO-2024140637-A1 OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-07-04 WO claimed
WO-2024051766-A1 MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-03-14 WO claimed
WO-2024032689-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-02-15 WO claimed
WO-2023151635-A1 COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF 标新生物医药科技(上海)有限公司 2023-08-17 WO claimed
WO-2023104155-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF 标新生物医药科技(上海)有限公司 2023-06-15 WO claimed
WO-2023066350-A1 CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS 标新生物医药科技(上海)有限公司 2023-04-27 WO claimed
WO-2003028641-A2 MCH RECEPTOR ANTAGONISTS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-04-10 WO claimed
EP-1294679-A1 BETA-AMINO ACID NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-03-26 EP claimed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO claimed
US-20020147188-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-10 US claimed
EP-0668860-B1 PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES UPJOHN CO (US) 2002-09-11 EP claimed
WO-2002055077-A1 USE OF IMIDAZOLYL CYCLIC ACETAL DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES MEDIATED BY THE ALK5 RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2002-07-18 WO claimed
WO-2001096285-A1 BETA-AMINO ACID NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-12-20 WO claimed
WO-2001070232-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-09-27 WO claimed
WO-2000078726-A1 IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES ELI LILLY AND COMPANY (US) 2000-12-28 WO claimed
WO-1994011361-A1 PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES THE UPJOHN COMPANY (US) 1994-05-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147188-A1 Protease inhibitors CTSK, MMP13, CTSZ ALDH1A1 3651/4885RAB9A 1322/4885SMN1; SMN2 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.